| Biomarker ID | 1195 |
| PMID | 23918943 |
| Year | 2013 |
| Biomarker | Methylation Status of MOB3B |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethylated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | Cohort 1: univariate : [HR = 1.351 (95% CI: 0.793-2.303), P-value=0.268] |
| Effect on Pathways | Pathways include: F2RL1 knockdown 96h HT29, NR1D2 knockdown 96h HT29, CAMK2D knockdown 96h HT29, AGTR1 knockdown 96h MCF7, FLT3 knockdown 96h MCF7 |
| Experiment | Biochemical recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Nonmalignant samples [(adjacent normal [ADJ-N], benign prostatic hyperplasia (BPH)( n = 35)] and radical prostatectomy (RP) samples (n = 293) were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.93 |
| Accuracy | NA |
| Level Of Significance | P < 0.001 |
| Method Used | quantitative methylation specific PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | MOB3B |